Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CLYM |
---|---|---|
09:32 ET | 9401 | 4.93 |
09:34 ET | 200 | 4.93 |
09:36 ET | 500 | 5.4 |
09:38 ET | 400 | 5.38 |
09:39 ET | 647 | 5.7 |
09:41 ET | 965 | 5.8 |
09:43 ET | 987 | 5.72 |
09:45 ET | 6529 | 5.67 |
09:48 ET | 1233 | 5.59 |
09:50 ET | 6366 | 5.56 |
09:52 ET | 3757 | 5.51 |
09:54 ET | 400 | 5.56 |
09:57 ET | 1781 | 5.52 |
09:59 ET | 2680 | 5.5 |
10:01 ET | 400 | 5.45 |
10:03 ET | 465 | 5.41 |
10:06 ET | 200 | 5.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Climb Bio Inc | 342.7M | -2.5x | --- |
Nautilus Biotechnology Inc | 342.4M | -4.9x | --- |
Monte Rosa Therapeutics Inc | 330.8M | -2.5x | --- |
Corvus Pharmaceuticals Inc | 330.3M | -12.0x | --- |
GH Research PLC | 328.8M | 0.0x | --- |
Biomea Fusion Inc | 366.8M | -2.6x | --- |
Eliem Therapeutics, Inc. is a biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. It also focuses on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing TNT119, an anti-CD19 antibody designed for a range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $342.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.1M |
Climb Bio Inc does not pay a dividend. | |
Beta | --- |
EPS | $-2.15 |
Book Value | $3.88 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.